Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02317900 · ClinicalTrials.gov registry record · Phase 1

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
2
Study locations

NCT02317900 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants, below the 3,976-participant average among 9 other Dengue trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02317900, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
2
Study locations

Study Summary

Dengue viruses are widespread in most tropical and subtropical regions of the world. This study will evaluate the safety and protective efficacy of a dengue vaccine (called TV005) against viremia and rash induced by a DENV-2 vaccine virus (called rDEN2∆30-7169) in healthy adults.

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL TV005
  • BIOLOGICAL rDEN2∆30-7169

Study Locations (2)

Maryland

  • Center for Immunization Research, Johns Hopkins School of Public Health - Baltimore

Vermont

  • University of Vermont Vaccine Testing Center - Burlington

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2014-12
Phase Phase 1

What the Registry Record Tells You About NCT02317900

The ClinicalTrials.gov registry entry for NCT02317900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,976-participant average among 9 other Dengue trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02317900 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Vermont.

Frequently Asked Questions

What is clinical trial NCT02317900 about?

NCT02317900 is a clinical study titled "Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults". Dengue viruses are widespread in most tropical and subtropical regions of the world. This study will evaluate the safety and protective efficacy of a dengue vaccine (called TV005) against viremia and rash induced by a DENV-2 vaccine virus (called rDEN2∆30-7169) in healthy adults.

What is the current status of trial NCT02317900?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-12.

What conditions does trial NCT02317900 study?

This clinical trial studies the following conditions: Dengue.

What interventions are being tested in trial NCT02317900?

The interventions under investigation include: Placebo (BIOLOGICAL), TV005 (BIOLOGICAL), rDEN2∆30-7169 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02317900?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02317900 being conducted?

This trial has 2 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dengue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.